NCT06914713 Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
| NCT ID | NCT06914713 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Henan University of Traditional Chinese Medicine |
| Condition | Idiopathic Pulmonary Fibrosis(IPF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 384 participants |
| Start Date | 2025-09-08 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 384 participants in total. It began in 2025-09-08 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui Huan-xian Formula for retarding the decline of pulmonary function in Idiopathic Pulmonary Fibrosis（IPF）
Eligibility Criteria
Inclusion Criteria: 1. Patients who meet the diagnostic criteria for IPF. 2. Pulmonary function: The percentage of forced vital capacity (FVC) to the predicted value is ≥ 50%; and the percentage of the diffusing capacity of the lung for carbon monoxide (DLCO) to the predicted value is ≥ 30%. 3. Patients who meet the syndrome - differentiation criteria for lung - qi deficiency syndrome, lung - and - kidney qi deficiency syndrome, etc. 4. Aged between 40 and 85 years old. 5. Patients who voluntarily accept the treatment and sign the informed consent Exclusion Criteria: 1. Patients in the acute exacerbation phase of IPF. 2. Patients complicated with other pulmonary diseases such as chronic obstructive pulmonary disease (COPD), lung cancer, active pulmonary tuberculosis, bronchiectasis, and pulmonary embolism. 3. Patients with severe joint, peripheral nerve, and peripheral vascular diseases that affect limb movement and who are bed - ridden for a long time and cannot complete the six - minute walk test. 4. Patients complicated with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, heart function grade 3 or above, stroke, cerebral hemorrhage, etc.). 5. Patients complicated with liver diseases such as cirrhosis or secondary portal hypertension, bleeding caused by esophageal and gastric varices, patients with kidney diseases requiring dialysis or kidney transplantation, or patients with abnormal liver and kidney functions (ALT, AST, and BUN are 1.5 times higher than the upper limit of the normal range, and blood Cr is higher than the upper limit of the normal range). 6. Patients with unclear consciousness, various mental illnesses, etc., who cannot communicate normally. 7. Pregnant or lactating women and patients with a recent plan for pregnancy. 8. Patients who have participated in other clinical trials within 1 month before enrollment. 9. Patients known to be allergic to any of the test medications and their components.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06914713 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 85 Years, studying Idiopathic Pulmonary Fibrosis(IPF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06914713 currently recruiting?
Yes, NCT06914713 is actively recruiting participants. Contact the research team at wmh107hn@163.com for enrollment information.
Where is the NCT06914713 trial being conducted?
This trial is being conducted at Zhengzhou, China.
Who is sponsoring the NCT06914713 clinical trial?
NCT06914713 is sponsored by Henan University of Traditional Chinese Medicine. The trial plans to enroll 384 participants.